Ser172
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser172  -  SOD3 (human)

Site Information
AsLAGPHsIVGRAVV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23147259

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 )
Disease tissue studied:
hepatocellular carcinoma, surrounding tissue ( 2 )
Relevant cell line - cell type - tissue:
hepatic-'liver, para-hepatocellular carcinoma tissue' ( 2 )

References 

1

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

2

Gu T (2009) CST Curation Set: 6577; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info